IL324764A - Prmt5 inhibitors - Google Patents

Prmt5 inhibitors

Info

Publication number
IL324764A
IL324764A IL324764A IL32476425A IL324764A IL 324764 A IL324764 A IL 324764A IL 324764 A IL324764 A IL 324764A IL 32476425 A IL32476425 A IL 32476425A IL 324764 A IL324764 A IL 324764A
Authority
IL
Israel
Prior art keywords
methyl
carboxamide
amino
quinolin
furo
Prior art date
Application number
IL324764A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ryvu Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics S A filed Critical Ryvu Therapeutics S A
Publication of IL324764A publication Critical patent/IL324764A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL324764A 2023-05-24 2024-05-23 Prmt5 inhibitors IL324764A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23461596 2023-05-24
EP24169443 2024-04-10
PCT/EP2024/064279 WO2024240894A1 (en) 2023-05-24 2024-05-23 Prmt5 inhibitors

Publications (1)

Publication Number Publication Date
IL324764A true IL324764A (en) 2026-01-01

Family

ID=91193326

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324764A IL324764A (en) 2023-05-24 2024-05-23 Prmt5 inhibitors

Country Status (7)

Country Link
EP (1) EP4720060A1 (de)
KR (1) KR20260015209A (de)
CN (1) CN121712770A (de)
AU (1) AU2024275020A1 (de)
IL (1) IL324764A (de)
MX (1) MX2025013985A (de)
WO (1) WO2024240894A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240101570A1 (en) * 2020-11-24 2024-03-28 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
AU2022217791A1 (en) * 2021-02-04 2023-08-17 Amgen Inc. Tricyclic-amido-bicyclic prmt5 inhibitors
US20240368153A1 (en) * 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
WO2024074611A1 (en) * 2022-10-05 2024-04-11 Ryvu Therapeutics S.A. Prmt5 inhibitors

Also Published As

Publication number Publication date
EP4720060A1 (de) 2026-04-08
MX2025013985A (es) 2026-01-07
CN121712770A (zh) 2026-03-20
WO2024240894A1 (en) 2024-11-28
AU2024275020A1 (en) 2025-11-13
KR20260015209A (ko) 2026-02-02

Similar Documents

Publication Publication Date Title
KR102912147B1 (ko) 치환된 피라졸로피리미딘 및 치환된 푸린 및 유비퀴틴-특이적-가공 프로테아제 1 (usp1) 억제제로서의 그의 용도
ES2971271T3 (es) Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
ES2958948T3 (es) Derivados de 2,3-dihidro-1H-pirrolo[3,4-c]piridin-1-ona como inhibidores de HPK1 para el tratamiento del cáncer
EP3466929B1 (de) Als pdk1-inhibitoren nützliche heterocyclische verbindungen
TWI628165B (zh) 具治療作用之組成物及其使用方法
AU2024227155A1 (en) Carboxy-benzimidazole GLP-1R modulating compounds.
AU2016366546B2 (en) Inhibitors of Bruton's tyrosine kinase and methods of their use
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
KR20200133747A (ko) 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물
AU2014233657A1 (en) Biaryl amide compounds as kinase inhibitors
WO2022228399A1 (zh) 三并环类usp1抑制剂及其用途
EP3902796B1 (de) (pyridin-2-yl)amin-derivate als tgf-beta r1 (alk5) inhibitoren zur behandlung von krebs
JP2022525199A (ja) Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
CN108698996A (zh) 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
TW201240971A (en) Fused heterocyclic compounds
IL301480A (en) Condensed heteroaryl compounds and their use as CAMKII inhibitors
AU2024275020A1 (en) Prmt5 inhibitors
WO2024074611A1 (en) Prmt5 inhibitors
JP2024532597A (ja) サイクリンｋ分解剤
WO2025215153A1 (en) Prmt5 inhibitors
KR20250166190A (ko) Gpr35 조절제로서 이용하기 위한 이환식 헤테로아릴 화합물
HK40063493A (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
HK40063493B (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer